Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announces the acquisition of Ignite Proteomics, LLC (“Ignite”), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite’s functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captured by standard genomic testing alone. Ignite operates a CLIA-certified laboratory and has an established Medicare Proprietary Laboratory Analyses (PLA) reimbursement pathway of approximately $2,200 per test.

Read the full article: Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection //

Source: https://www.businesswire.com/news/home/20260313909767/en/Aditxt-Acquires-Ignite-Proteomics-to-Address-a-Critical-Challenge-in-Cancer-Care-Optimizing-Therapy-Selection

Scroll to Top